... Too many proinflammatory IL molecules lead to uncontrolled inflammation — causing diseases like spondylitis.There are currently three FDA-approved IL-17 inhibitors for treating ankylosing spondylitis and nr-axSpA: Bimekizumab-bkzx (Bimzelx) — Blocks both IL-17A and IL-17F, making it an option for people who haven’t responded to TNF or other IL inhibitors ...
... Too many proinflammatory IL molecules lead to uncontrolled inflammation — causing diseases like spondylitis.There are currently three FDA-approved IL-17 inhibitors for treating ankylosing spondylitis and nr-axSpA: Bimekizumab-bkzx (Bimzelx) — Blocks both IL-17A and IL-17F, making it an option for people who haven’t responded to TNF or other IL inhibitors ...